shareholder
Logo
Partner Content offre aux organisations l'accès au réseau de L'Echo. Le partenaire impliqué est responsable du contenu.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Ghent, Belgium, 27 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that a total number of 286 Executive Share Options (as defined below) has been exercised.

As a result of this exercise of Executive Share Options, on 27 July 2021 the share capital of the Company has increased from EUR 1,924,846.39 to EUR 1,924,931.96 and the number of issued and outstanding shares has increased from 18,576,252 to 18,577,078 shares, through the issuance of a total of 826 new shares.

The total current number of outstanding subscription rights amounts to 2,248,427, which entitles their holders (if exercised) to subscribe to 2,723,767 new shares with voting rights in total, namely:

  • 302,804 new shares can be issued upon the exercise of one subscription right that was granted in 2016 to Bootstrap Europe S.C.SP. (the “Bootstrap Subscription Right”);
  • 264,073 new shares can be issued upon the exercise of 91,536 share options that are still outstanding under the ‘Executive Share Options’ plan for staff members and consultants of the Company, entitling the holder thereof to acquire ca. 2.88 shares when exercising one share option (the “Executive Share Options”);
  • 1,156,890 new shares can be issued upon the exercise of 1,156,890 share options (each share option having the form of a subscription right) that are still outstanding under the ‘2018 Share Options’ plan for directors, employees and other staff members of the Company and its subsidiaries, entitling the holder thereof to acquire one new share when exercising one share option (the “2018 Share Options”); and
  • 1,000,000 new shares can be issued upon the exercise of 1,000,000 share options (each share option having the form of a subscription right) that are still outstanding under the ‘2021 Share Options’ plan for directors, employees and other staff members of the Company and its subsidiaries, entitling the holder thereof to acquire one new share when exercising one share option (the “2021 Share Options”).

Lisez le communiqué de presse ici.

 

Logo
Partner Content offre aux organisations l'accès au réseau de L'Echo. Le partenaire impliqué est responsable du contenu.
Publicité
Publicité
Publicité